EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate [Yahoo! Finance]
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: Yahoo! Finance
What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion. In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose. The model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the actual nasal passage. The results showed that the drug spreads well in the nose areas, where it can be quickly absorbed into the brain. Also Read: EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury Why It Matters: Oragenics is now preparing to move forward with human testing (Phase 2) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
OGEN
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- OGEN's page on the SEC website